Structural design of the anti-TNFα therapeutic NANOBODY® compound, ozoralizumab, to support its potent and sustained clinical efficacy
- PMID: 39083975
- DOI: 10.1016/j.bbrc.2024.150454
Structural design of the anti-TNFα therapeutic NANOBODY® compound, ozoralizumab, to support its potent and sustained clinical efficacy
Conflict of interest statement
Declaration of competing interest The authors certify that all of their affiliations and/or financial involvement with any organization, or any financial conflicts with the subject matter discussed in the manuscript are disclosed in the Acknowledgement section of the manuscript.
LinkOut - more resources
Full Text Sources